Trophoblast Cell Surface Antigen 2 (Trop-2) Protein is Highly Expressed in Salivary Gland Carcinomas and Represents a Potential Therapeutic Target.
Adolescent
Adult
Aged
Aged, 80 and over
Antigens, Neoplasm
/ metabolism
Biomarkers, Tumor
/ metabolism
Carcinoma
/ metabolism
Cell Adhesion Molecules
/ metabolism
Female
Humans
Immunohistochemistry
Male
Middle Aged
Retrospective Studies
Salivary Gland Neoplasms
/ metabolism
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
Young Adult
Immunoconjugates
Immunohistochemistry
Mass
Matrix-assisted laser desorption/ionization
Molecular targeted therapy
Retrospective studies
Salivary gland neoplasms
Spectrometry
Journal
Head and neck pathology
ISSN: 1936-0568
Titre abrégé: Head Neck Pathol
Pays: United States
ID NLM: 101304010
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
23
11
2020
accepted:
10
02
2021
pubmed:
23
4
2021
medline:
23
3
2022
entrez:
22
4
2021
Statut:
ppublish
Résumé
Treatment options for unresectable, recurrent or metastatic salivary gland carcinomas (SGC) are scarce. Trophoblast cell surface antigen 2 (Trop-2) is a transmembrane glycoprotein that is involved in a variety of oncogenic cell signaling pathways. Its potential as a target for the antibody-drug conjugate sacituzumab govitecan has already been demonstrated in different tumor entities. The United States Food and Drug Administration approved this antibody-drug conjugate for the treatment of metastatic triple-negative breast cancer. Here, we aimed to investigate Trop-2 protein expression in different entities of SGCs. We retrospectively reviewed the medical records of all patients that underwent surgery for a primary SGC in a tertiary referral center between 1990 and 2014. Immunohistochemical (IHC) staining for Trop-2 was performed and rated as negative, weak, moderate or high using a semiquantitative score. Additionally, representative cases were analyzed using MALDI-mass spectrometry (MS) imaging to confirm the IHC results. The cohort consisted of 114 tumors of the parotid gland (90.4%) and submandibular gland (9.6%). It mainly included mucoepidermoid, salivary duct and adenoid cystic carcinomas. In IHC samples, 44% showed high, 38% moderate and 10% weak expression rates of Trop-2. MALDI-MS imaging confirmed the presence of Trop-2 protein in 80% of the tested tumor samples. This is the first study to demonstrate that several types of SGC express Trop-2 with variable intensity. Since there are currently few systemic treatment options for advanced SGCs, Trop-2 represents a promising target for further clinical studies, for instance, with sacituzumab govitecan.
Identifiants
pubmed: 33886073
doi: 10.1007/s12105-021-01325-5
pii: 10.1007/s12105-021-01325-5
pmc: PMC8633075
doi:
Substances chimiques
Antigens, Neoplasm
0
Biomarkers, Tumor
0
Cell Adhesion Molecules
0
TACSTD2 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1147-1155Informations de copyright
© 2021. The Author(s).
Références
Lancet Oncol. 2017 May;18(5):640-653
pubmed: 28343975
Oncotarget. 2017 Jan 17;8(3):3946-3956
pubmed: 27992367
Cancers (Basel). 2020 Aug 31;12(9):
pubmed: 32878206
Invest New Drugs. 2018 Oct;36(5):836-847
pubmed: 29333575
J Oral Pathol Med. 2020 Aug;49(7):606-616
pubmed: 32430929
Acta Otolaryngol. 2018 Jan;138(1):73-79
pubmed: 28899226
Onco Targets Ther. 2019 Mar 01;12:1781-1790
pubmed: 30881031
Cancer Imaging. 2014 Apr 29;14:19
pubmed: 25609190
Oncotarget. 2020 Nov 10;11(45):4123-4137
pubmed: 33227073
Bioconjug Chem. 2015 May 20;26(5):919-31
pubmed: 25915780
Mol Clin Oncol. 2019 Aug;11(2):111-115
pubmed: 31281644
Lancet Oncol. 2020 Apr;21(4):531-540
pubmed: 32105622
Clin Genitourin Cancer. 2016 Feb;14(1):e75-9
pubmed: 26541586
Surg Pathol Clin. 2017 Mar;10(1):155-176
pubmed: 28153132
Front Oncol. 2020 Sep 30;10:572493
pubmed: 33102230
J Clin Oncol. 2017 Aug 20;35(24):2790-2797
pubmed: 28548889
Ther Adv Med Oncol. 2020 May 20;12:1758835920917571
pubmed: 32547645
Genes Cancer. 2015 Mar;6(3-4):84-105
pubmed: 26000093
Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1044-50
pubmed: 16965870
Radiat Oncol. 2016 Mar 22;11:47
pubmed: 27000157
Clin Cancer Res. 2017 Oct 1;23(19):5711-5719
pubmed: 28679770
Biochim Biophys Acta. 2012 Jan;1819(1):28-37
pubmed: 21978825
J Laryngol Otol. 2016 May;130(S2):S142-S149
pubmed: 27841127
Eur Ann Otorhinolaryngol Head Neck Dis. 2016 Feb;133(1):13-7
pubmed: 26493113
Radiother Oncol. 2017 Jun;123(3):387-393
pubmed: 28528680
Laryngoscope. 2010 Jan;120(1):65-70
pubmed: 19877226
Eur J Gynaecol Oncol. 2016;37(1):113-6
pubmed: 27048121
Oral Oncol. 2017 Nov;74:40-48
pubmed: 29103750
Laryngoscope. 2017 Sep;127(9):2057-2062
pubmed: 28194862
N Engl J Med. 2019 Feb 21;380(8):741-751
pubmed: 30786188
Sci Rep. 2016 Sep 20;6:33658
pubmed: 27645103
Oral Oncol. 2017 Mar;66:58-63
pubmed: 28249649
Mol Cancer. 2010 Sep 21;9:253
pubmed: 20858281
Int J Radiat Oncol Biol Phys. 2007;69(2 Suppl):S52-5
pubmed: 17848295
Oncotarget. 2015 Sep 8;6(26):22496-512
pubmed: 26101915
Head Neck Pathol. 2017 Mar;11(1):55-67
pubmed: 28247227